Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
SYRE Stock Chart & Stats
$30.14
-$0.27(-1.11%)
At close: 4:00 PM EST
$30.14
-$0.27(-1.11%)
Day’s Range― - ―
52-Week Range$10.91 - $35.31
Previous CloseN/A
Volume84.75K
Average Volume (3M)770.07K
Market Cap
$2.38B
Enterprise Value$532.42M
Total Cash (Recent Filing)$486.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Feb 26, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding77,592,130
10 Day Avg. Volume536,915
30 Day Avg. Volume770,071
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.11
Price to Sales (P/S)0.00
P/FCF Ratio-6.96
Enterprise Value/Market Cap0.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.77
Enterprise Value/Ebitda-2.99
Forecast
1Y Price Target
$56.67Price Target Upside88.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ExpansionInitiation of a Phase 2 signal-finding trial for SPY072 across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis expands the clinical pipeline and increases the chance of identifying new therapeutic opportunities.
Pharmacokinetics And DosingLong half-life data for core antibody programs support infrequent dosing every few months, which could boost patient convenience, adherence, and competitive differentiation.
Target Validation And Market PotentialMultiple biological studies show TL1A upregulation in rheumatoid arthritis and preclinical data showed SPY072 reduced disease measures, supporting TL1A as a credible new mechanism that could open a meaningful market if human proof-of-concept is positive.
Bears Say
Commercial And Adoption RiskSPY072 must overcome competitive pressures and real-world adoption challenges before achieving broad commercial success even if clinical efficacy is demonstrated.
Uncertain Efficacy In Specific IndicationsEvidence for benefit in psoriatic arthritis and axial spondyloarthritis is mixed, leaving those indications uncertain until human proof-of-concept data confirm efficacy.
Weak Translational SupportConflicting TL1A expression patterns and a lack of established animal models for axSpA and PsA weaken translational support and increase the risk that preclinical signals may not translate to patients.
Spyre Therapeutics News
SYRE FAQ
What was Spyre Therapeutics’s price range in the past 12 months?
Spyre Therapeutics lowest stock price was $10.91 and its highest was $35.31 in the past 12 months.
What is Spyre Therapeutics’s market cap?
Spyre Therapeutics’s market cap is $2.38B.
When is Spyre Therapeutics’s upcoming earnings report date?
Spyre Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 44 days.
How were Spyre Therapeutics’s earnings last quarter?
Spyre Therapeutics released its earnings results on Nov 04, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.761 by $0.611.
Is Spyre Therapeutics overvalued?
According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued.
Does Spyre Therapeutics pay dividends?
Spyre Therapeutics does not currently pay dividends.
What is Spyre Therapeutics’s EPS estimate?
Spyre Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Spyre Therapeutics have?
Spyre Therapeutics has 77,592,130 shares outstanding.
What happened to Spyre Therapeutics’s price movement after its last earnings report?
Spyre Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.761. Following the earnings report the stock price went down -0.566%.
Which hedge fund is a major shareholder of Spyre Therapeutics?
Currently, no hedge funds are holding shares in SYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spyre Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.67 (88.02% Upside)
$56.67 (88.02% Upside)
Blogger Sentiment
Bullish
SYRE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 273.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.47%
12-Months-Change
Fundamentals
Return on Equity
-32.63%
Trailing 12-Months
Asset Growth
19.83%
Trailing 12-Months
Company Description
Spyre Therapeutics
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
SYRE Stock 12 Month Forecast
Average Price Target
$56.67
▲(88.02% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Oculis Holding
―
Upstream Bio, Inc.
―
Ownership Overview
7.43% Insiders
19.32% Mutual Funds
45.74% Other Institutional Investors
17.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---